Yeghiazaryan Nune S, Zara Federico, Capovilla Giuseppe, Brigati Giorgia, Falsaperla Raffaele, Striano Pasquale
Armenian Republican Epilepsy Centre Erebouni, Yerevan State Medical University, Yerevan, Armenia.
J Paediatr Child Health. 2012 Mar;48(3):E113-5. doi: 10.1111/j.1440-1754.2010.01866.x. Epub 2010 Oct 6.
Pyridoxine-dependent epilepsy (PDE) is a rare autosomal recessive disorder causing intractable seizures in neonates and infants. PDE patients are typically resistant to anti-epileptic treatment but respond to the administration of pyridoxine. Different seizure types have been reported in PDE, and episodes of status epilepticus are common. Electroencephalographic or neuroimaging abnormalities are not pathognomonic for this disorder. Intellectual disability is frequent at the follow-up. Recently, elevated urinary α-aminoadipic semialdehyde has been shown to be a reliable biomarker of this disorder, and mutations in the ALDH7A1 gene, encoding α-aminoadipic semialdehyde dehydrogenase, have been demonstrated in the large majority of PDE patients. However, early consideration of a pyridoxine trial remains the most important issue in a neonate or in an infant with intractable early onset seizures.
吡哆醇依赖性癫痫(PDE)是一种罕见的常染色体隐性疾病,可导致新生儿和婴儿出现难治性癫痫发作。PDE患者通常对抗癫痫治疗有抵抗性,但对吡哆醇给药有反应。PDE中已报告了不同的癫痫发作类型,癫痫持续状态发作很常见。脑电图或神经影像学异常并非该疾病的特征性表现。随访中智力残疾很常见。最近,尿中α-氨基己二酸半醛升高已被证明是该疾病的可靠生物标志物,并且在大多数PDE患者中已证实编码α-氨基己二酸半醛脱氢酶的ALDH7A1基因突变。然而,对于患有难治性早发性癫痫发作的新生儿或婴儿,尽早考虑进行吡哆醇试验仍然是最重要的问题。